{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-033839","form_type":"8-K","ticker":"TELA","cik":"0001561921","company_name":"TELA Bio, Inc.","filed_at":"2026-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.441049+00:00","generated_at":"2026-05-15T09:12:08.385189+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TELA Bio Q4 2025 revenue $20.9M (+18% YoY); guides FY26 growth at least 8%","bullets":["Q4 2025 revenue $20.9M (+18% YoY); FY 2025 revenue $80.3M (+16% YoY).","Net loss Q4 2025 $9.0M vs $9.2M prior year; FY net loss $38.8M vs $37.8M.","Closed $70M credit facility from Perceptive Advisors; $60M drawn at closing, $10M option by Apr 2027.","Promoted Howard Langstein, MD, FACS to Chief Medical Officer effective March 1, 2026.","FY 2026 revenue guidance: at least 8% growth; Q1 2026 revenue expected ~$18.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-033839","json":"https://secwatch.observer/filing/0001104659-26-033839.json","markdown":"https://secwatch.observer/filing/0001104659-26-033839.md","text":"https://secwatch.observer/filing/0001104659-26-033839.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926033839/0001104659-26-033839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926033839/tm269387d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:12:08.385189+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b1a4fc894517c76bda5bc266aa4019ffe6fe8f9b","claim":"TELA Bio, Inc. reported financial results for the fourth quarter of 2025 and the fiscal year ended December 31, 2025.","evidence_excerpt":"On March 24, 2026, TELA Bio, Inc. (the \" Company \") issued a press release announcing its financial results for the fourth quarter of 2025 and the fiscal year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926033839/0001104659-26-033839-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2025 and the fiscal year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}